AltrixBio has developed LuCI™, an oral drug that adheres to the gastrointestinal tract to modulate nutrient absorption and lower glucose levels, mimicking the metabolic effects of bariatric surgery. This approach offers a less invasive, cost-effective alternative for managing type-2 diabetes in patients who are not suitable candidates for surgical intervention.
Funding
$30K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Type 2 diabetes (T2D) is a widespread condition often exacerbated by obesity, leading to severe complications such as blindness, amputation, and renal failure. While bariatric surgeries have demonstrated effectiveness in achieving diabetes remission, they are invasive, costly, and unsuitable for many patients. Existing medical management strategies often fall short of providing optimal outcomes for these individuals.
Solution
AltrixBio offers LuCI™, an orally administered drug designed to mimic the metabolic benefits of bariatric surgery without the need for an invasive procedure. LuCI™ adheres to the gastrointestinal (GI) tract, modulating nutrient absorption and lowering glucose levels. The drug binds temporarily to the bowel, acting locally without systemic absorption, which may limit side effects. By restricting the absorption of fats and glucose through the bowel mucosa, LuCI™ helps reduce glucose levels, offering a more financially feasible and less risky alternative to bariatric surgery for managing T2D. Pre-clinical models have demonstrated LuCI™'s ability to modulate nutrient contact with the bowel mucosa and lower the glucose response.
Target Audience
The primary target audience includes patients with type 2 diabetes who are not suitable candidates for bariatric surgery, as well as physicians interested in offering a less invasive treatment option.
Features
- Oral drug formulation for convenient administration.
- GI tract adhesion for targeted drug delivery.
- Modulation of nutrient absorption to control glucose levels.
- Local action in the bowel with limited systemic absorption.
- Potential as a platform for delivery of biologics to the GI tract.